MA28436B1 - Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs - Google Patents

Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs

Info

Publication number
MA28436B1
MA28436B1 MA29277A MA29277A MA28436B1 MA 28436 B1 MA28436 B1 MA 28436B1 MA 29277 A MA29277 A MA 29277A MA 29277 A MA29277 A MA 29277A MA 28436 B1 MA28436 B1 MA 28436B1
Authority
MA
Morocco
Prior art keywords
symptoms
estrogen receptor
vasomote
treatment
selective modulators
Prior art date
Application number
MA29277A
Other languages
English (en)
Inventor
Robert Dean Dally
Jeffrey Alan Dodge
Scott Alan Frank
Ronald Jay Hinklin
Timothy Alan Shepherd
Owen Brendan Wallace
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA28436B1 publication Critical patent/MA28436B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à un modulateur de récepteur d'oestrogène sélectif de formule I: ou à son sel d'addition d'un acide pharmaceutique ; utile pour traiter les symptômes vasomoteurs.
MA29277A 2004-01-22 2006-08-18 Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs MA28436B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53844204P 2004-01-22 2004-01-22
US53834204P 2004-01-22 2004-01-22

Publications (1)

Publication Number Publication Date
MA28436B1 true MA28436B1 (fr) 2007-02-01

Family

ID=34830456

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29277A MA28436B1 (fr) 2004-01-22 2006-08-18 Modulateurs selectifs du recepteur des oestrogenes pour le traitement de symptômes vasomoteurs

Country Status (20)

Country Link
US (2) US20090023917A1 (fr)
EP (1) EP1709021B1 (fr)
JP (1) JP4909086B2 (fr)
KR (2) KR100849559B1 (fr)
CN (1) CN102250042A (fr)
AT (1) ATE476428T1 (fr)
AU (1) AU2005207821B2 (fr)
BR (1) BRPI0506721A (fr)
CA (1) CA2551956C (fr)
CR (1) CR8517A (fr)
DE (1) DE602005022673D1 (fr)
EA (2) EA012262B1 (fr)
EC (1) ECSP066711A (fr)
ES (1) ES2347973T3 (fr)
IL (1) IL176738A0 (fr)
MA (1) MA28436B1 (fr)
NO (1) NO20063760L (fr)
SG (1) SG149867A1 (fr)
UA (1) UA85862C2 (fr)
WO (1) WO2005073204A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656067C (fr) 2006-06-23 2014-08-12 Radius Health, Inc. Traitement de symptomes vasomoteurs par des modulateurs des recepteurs d'oestrogene selectifs
WO2008009079A2 (fr) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Ptéridines substituées utilisables pour le traitement et la prévention des infections virales
WO2008009078A2 (fr) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
MX2011003383A (es) * 2008-09-29 2011-04-21 Lilly Co Eli Modulador selectivo del receptor de estrogeno para el tratamiento de osteoartritis.
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
PL2568806T3 (pl) 2010-05-12 2017-03-31 Radius Health, Inc. Schematy lecznicze
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
FR3014434B1 (fr) * 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SG11201606876RA (en) 2015-03-04 2016-10-28 Gilead Sciences Inc Toll like receptor modulator compounds
WO2017223115A1 (fr) 2016-06-22 2017-12-28 Radius Health, Inc. Méthodes ar+ de traitement du cancer du sein
SI3507276T1 (sl) 2016-09-02 2022-01-31 Gilead Sciences, Inc. Spojine modulatorja toličnih receptorjev
WO2018045150A1 (fr) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Dérivés de 4,6-diamino-pyrido [3,2-d] pyrimidine en tant que modulateurs du récepteur de type toll
EP3565542B1 (fr) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Formes polymorphes de rad1901-2hcl
CN108675999B (zh) * 2018-05-09 2021-03-16 浙江农林大学暨阳学院 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
PE20241731A1 (es) 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5726186A (en) * 1995-09-08 1998-03-10 Eli Lilly And Company Pentacyclic compounds, intermediates, processes, compositions, and methods
CA2213810C (fr) * 1996-08-29 2006-06-06 Lewis Dale Pennington Benzo¬b|thiophenes, intermediaires, procedes, compositions et methodes
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
CA2217810A1 (fr) * 1996-10-10 1998-04-10 Eli Lilly And Company Composes 2-aryl-3-aminoaryloxynaphtyliques, intermediaires, compositions et methodes
CA2298651A1 (fr) * 1997-08-07 1999-02-18 Jeffrey Alan Dodge Composes 1-{4-(substitues alkoxy)benzyl}naphtalene possedant une activite inhibitrice d'oestrogenes
PL374845A1 (en) * 2002-07-22 2005-11-14 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group

Also Published As

Publication number Publication date
ATE476428T1 (de) 2010-08-15
JP4909086B2 (ja) 2012-04-04
US20090023917A1 (en) 2009-01-22
KR100849559B1 (ko) 2008-07-31
CN102250042A (zh) 2011-11-23
AU2005207821B2 (en) 2011-02-10
SG149867A1 (en) 2009-02-27
KR20060129277A (ko) 2006-12-15
DE602005022673D1 (de) 2010-09-16
KR101008804B1 (ko) 2011-01-14
EP1709021A1 (fr) 2006-10-11
UA85862C2 (uk) 2009-03-10
US20110281847A1 (en) 2011-11-17
EA200900586A1 (ru) 2009-08-28
AU2005207821A1 (en) 2005-08-11
IL176738A0 (en) 2006-10-31
WO2005073204A1 (fr) 2005-08-11
CA2551956C (fr) 2013-05-07
ECSP066711A (es) 2006-10-31
US8217032B2 (en) 2012-07-10
CR8517A (es) 2006-12-01
ES2347973T3 (es) 2010-11-26
EP1709021B1 (fr) 2010-08-04
BRPI0506721A (pt) 2007-05-02
KR20080016755A (ko) 2008-02-21
CA2551956A1 (fr) 2005-08-11
EA200601353A1 (ru) 2007-02-27
EA012262B1 (ru) 2009-08-28
EA016613B1 (ru) 2012-06-29
NO20063760L (no) 2006-10-16
JP2007519721A (ja) 2007-07-19

Similar Documents

Publication Publication Date Title
NO20063760L (no) Selektive ostrogenreseptormodulatorer for behandling av vasomotoriske symptomer
EA200870424A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
EA201170043A1 (ru) Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений
FR3004920B1 (fr) Dispositif d'osteotomie, en particulier pour la realisation du scarf extreme dans le traitement de l'hallux valgus severe.
EP2059210A4 (fr) Dispositifs thérapeutiques pour le traitement de divers états chez la femme
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
ATE523497T1 (de) Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MX338217B (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-a rilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades.
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
BR0312675A (pt) Composto ou um sal de adição de ácido farmacêutico do mesmo,m e, métodos para tratar endometriose, e para tratar leiomioma uterino
TW200738669A (en) Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
WO2011009534A3 (fr) Dérivés 17-hydroxy-17-pentafluoroéthyl-estra-4,9(10)-diène-11-aryle, procédés de préparation et utilisation pour le traitement de maladies
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
ATE473741T1 (de) Neue imidazolopyrazolderivate als selektive androgen-rezeptor-modulatoren
EA201000732A1 (ru) Производные s-алкилизотиурония для лечения нарушений, обусловленных гиперсократимостью матки
ATE482195T1 (de) Benzoäfüisoindole als antagonisten des ep4- rezeptors
EP2500409A4 (fr) Dispositif permettant de moduler l'expression de pgc-1, et dispositif de traitement et méthode de traitement pour maladie ischémique
ATE448215T1 (de) Selektive östrogen-rezeptor-modulatoren
EA200702604A1 (ru) Производные бензофуранона как нестероидные модуляторы рецептора прогестерона